key: cord-0783168-a2e966c0
authors: Tan, Rachel Si Jing; ng, Ka Ti; Xin, Chua Ee; Atan, Rafidah; Yunos, Nor'azim Mohd; Hasan, M. Shahnaz
title: High Dose versus Low Dose Corticosteroids in COVID-19 patients: a systematic review and meta-analysis
date: 2022-05-13
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2022.05.011
sha: 860c4cd1e1022bc46390688d79f3275081819a24
doc_id: 783168
cord_uid: a2e966c0

Objectives : The clinical efficacy of corticosteroids remains unclear. The primary aim of this systematic review and meta-analysis was to evaluate the use of high dose versus low dose corticosteroids on the mortality rate of COVID-19 patients. Design : Systematic Review and Meta-analysis Setting : Electronic search for randomized controlled trials and observational studies (MEDLINE, EMBASE, CENTRAL) Participants : Hospitalized adults ≥ 18 years old who are SARS-CoV-2 PCR positive Interventions : High dose and low dose corticosteroids Measurements and Main Results : A total of twelve studies (n=2759 patients) were included in this review. Our pooled analysis demonstrated no significant difference in mortality rate between the high dose and low dose corticosteroids groups (n=2632; OR: 1.07 [95%CI 0.67, 1.72], p=0.77, I2=76%, trial sequential analysis=inconclusive). No significant differences were observed in the incidence of intensive care unit (ICU) admission rate (n=1544; OR: 0.77[95%CI 0.43, 1.37], p=0.37, I2= 72%), duration of hospital stay (n=1615; MD: 0.53[95%CI -1.36, 2.41], p=0.58, I2=87%), respiratory support (n=1694; OR: 1.51[95%CI 0.77, 2.96], p=0.23, I2=84%), duration of mechanical ventilation (n=419; MD: -1.44[95%CI -4.27, 1.40], p=0.32, I2=93%), incidence of hyperglycemia (n=516, OR: 0.91[95%CI 0.58, 1.43], p=0.68, I2=0%) and infection rate (n=1485, OR: 0.86[95%CI 0.64, 1.16], p=0.33, I2=29%). Conclusion : Our meta-analysis demonstrated high dose corticosteroids did not reduce mortality rate. However, high dose corticosteroids do not pose higher risk of hyperglycemia and infection rate for COVID-19 patients. Due to the inconclusive trial sequential analysis, substantial heterogeneity and low level of evidence, future large-scale randomized clinical trials are warranted to improve the certainty of evidence for the use of high dose compared to low dose corticosteroids in COVID-19 patients. Keywords

The clinical efficacy of corticosteroids remains unclear. The primary aim of this systematic review and meta-analysis was to evaluate the use of high dose versus low dose corticosteroids on the mortality rate of COVID-19 patients. 

Our meta-analysis demonstrated high dose corticosteroids did not reduce mortality rate.

However, high dose corticosteroids do not pose higher risk of hyperglycemia and infection rate for COVID-19 patients. Due to the inconclusive trial sequential analysis, substantial heterogeneity and low level of evidence, future large-scale randomized clinical trials are

In March 2020, the World Health Organization (WHO) had declared coronavirus disease 2019 (COVID-19) as a global pandemic (1) . As of 1 st February 2021, more than 100 million people have been diagnosed with COVID-19, and more than 2 million deaths were reported (2) . It is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which belongs to the same family of human coronaviruses as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) (3, 4) .

The severity of COVID-19 varies from asymptomatic to severe ARDS manifestation, which requires mechanical ventilator support, intensive care unit (ICU) admission, long duration of hospital stay and high mortality rate. (5) (6) (7) . Evidence suggests that COVID-19 is associated with dysregulated coagulation cascade and excessive release of pro-inflammatory cytokines (8) (9) (10) ,leading to diffuse pulmonary injury (4) . Corticosteroids are anti-inflammatory and immunomodulatory agent, which had been used as part of the treatment during the outbreak of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in 2012 and Severe Acute Respiratory Syndrome coronavirus-1 (SARS-CoV-1) in 2002 (11, 12) .

In this current COVID-19 pandemic, corticosteroids use is believed to suppress the inflammatory response of COVID-19 on the lung tissues, leading to less severe lung injury and better recovery outcomes. The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial is one of the largest COVID-19 trials demonstrated that dexamethasone reduced the 28-day mortality in COVID-19 patients who required supplemental oxygen (13) .

Subsequently, the updated guidelines from the World Health Organization (WHO) and the National Institute of Health (NIH) strongly recommend the use of corticosteroids for COVID-19 patients who require mechanical ventilation or extracorporeal membrane oxygenation (ECMO) or severe COVID-19 patients, albeit advise against its use in mild to moderate or non-severe COVID-19 patient (14, 15) . However, the dosage of corticosteroids used among COVID-19 patients varied across different hospitals and countries (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) .

Several clinical studies were conducted to investigate the role of high dose versus low dose corticosteroids as part of the treatment of COVID-19 with conflicting findings (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . At present, the efficacy and safety profile of high dose versus low dose corticosteroids remain unclear in the literature. Thus, a systematic review is warranted to synthesize evidence on the use of high dose and low dose of corticosteroids in COVID-19 patients before any recommendations can be made.

We hypothesized that high dose corticosteroids reduced the mortality rate in COVID-19

patients. The primary objective of this systematic review and meta-analysis was to investigate the clinical effects of high dose and low dose corticosteroids on the mortality rate of COVID-19 patients. Secondary aims were to examine the effect of high dose and low dose corticosteroids on the ICU admission rate, duration of hospital stay, and the number of patients needing ventilation.

The protocol of this systematic review and meta-analysis was registered prospectively on a public database (PROSPERO-CRD42021249784). The systematic review was reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (28) . The Population, Intervention, Control and Outcomes (PICO) framework was used to formulate our review questions (Online Supplementary Table A .1).

The author-defined high dose and low dose corticosteroids were used as our inclusion criteria.

Our inclusion criteria of high dose corticosteroids is methylprednisolone >100mg/day or equivalent and dexamethasone >20mg/day as high dose corticosteroids, any dose lower than high dose corticosteroids is considered as low dose corticosteroids. Primary outcome of this review was mortality rate. Secondary outcomes included the incidence of ICU admission rate, duration of hospital stay, respiratory support, duration of mechanical ventilation, incidence of hyperglycemia and infection rate. to identify potential articles that can be included in our study. Given the data provided online is not extractable, we request raw data from the authors of the potential articles.

Inclusion criteria were all randomized controlled trials (RCTs) and observational studies comparing high dose versus low dose corticosteroids in hospitalized COVID-19 adult patients (aged 18 years and above). Case reports, case series, reviews (non-systematic), nonhuman studies, letters and conference abstracts were excluded.

All titles, abstracts and full texts screening were conducted in accordance with our inclusion and exclusion criteria by two authors (RT and CE) independently. A third author (KN) resolved any disagreements during the screening process. Data extraction was performed by two authors (RT and CE) independently using an online data collection sheet. Any median and interquartile range data were converted to mean and standard deviation (29) . Along with all measured outcomes, other relevant data namely, authors' name, year of publication, study design, sample size, dosage of corticosteroids and duration of corticosteroids used were extracted.

Risk of bias assessment of all included studies was conducted by two authors (RT and CE) independently. Newcastle-Ottawa Scale (NOS) was used to assess the quality of observational studies. NOS comprises of three domains, namely selection of study groups, comparability of groups and ascertainment of outcomes in cohort studies (30) . Articles are considered as high-risk bias and low risk bias with a score of < 7 and 7, respectively. All the included RCTs were evaluated with the Cochrane Risk of Bias Assessment Tool, which included assessment of selection bias, performance bias, detection bias, attrition bias, reporting bias and other potential sources of bias (31) . A third author (KN) adjudicated any discrepancy in the process of assessing the quality of the articles. We also adopt the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach to assess the quality of evidence for each measured outcomes based on several domains namely study design, risk of bias, inconsistency, indirectness, imprecision, and publication bias (32).

Review Manager, version 5.4, was used for statistical analysis. Dichotomous and continuous data were presented in Odds Ratio (OR) and Mean Difference (MD), respectively with 95% confidence interval (CI). Statistical heterogeneity was assessed using I-square (I 2 ) test. I 2 statistic < 40%, 40-60% and 60% were considered as low, moderate and high heterogeneity, respectively. A fixed-effect model was used for all the measured outcomes. If substantial heterogeneity was observed, a random-effect model was used for data analysis. Subgroup analysis was performed on the mortality rate based on the types of corticosteroids and respiratory support based on types of mechanical ventilation.

Trial sequential analysis was performed on the primary outcome (mortality) to assess the risk of random error and multiplicity phenomenon due to repeated significant testing in metaanalyses (33) (Figure 2 ). The required meta-analysis information size and adjusted significance thresholds were calculated based on a two-sided sequential analysis-adjusted random effects model with 5% risk of type 1 error and power of 80%.

Our search strategy yielded a total of 28318 articles and forty-seven articles fulfilled the inclusion and exclusion criteria for full-text screening ( Figure 1 ). Of these, twelve studies (total sample size: 2759 patients) were eligible for qualitative synthesis and data pooling (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Our search identified one ongoing RCT (Online Supplementary Table A 

The clinical characteristic of each study is tabulated in Table 1 . Of all included studies, there were eight observational studies (16, (18) (19) (20) (21) 23, 25, 26) , one quasi experimental study (17) and three RCTs (22, 24, 27) .The types of corticosteroids used varied across studies, namely methylprednisolone, dexamethasone, prednisolone, prednisone, and hydrocortisone. Three studies used solely one type of corticosteroids (16, 24, 27) , eight studies used more than one type of corticosteroids (17, 18, (20) (21) (22) (23) 25, 26) and one study did not specify the type of corticosteroid used (19) .The respective dose of each type of corticosteroids were methylprednisolone <0.5mg/kg/day to 500mg/day, dexamethasone 6mg/day to 40mg/day, hydrocortisone <200mg/day to ≥300mg/day and prednisone <0.5mg/kg/day to >0.5mg/kg/day. The duration of low dose and high dose corticosteroids regime varied from 3 days to day of hospital discharge.

The summary of risk of bias assessment (The Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool) and GRADE approach are presented in Online Supplementary Table A.5 and   Table 2 , respectively. All observational studies were overall low risk of bias (16, (18) (19) (20) (21) 23, 26) . Among all the included observational studies, four of them did not match of the clinical characteristics between high and low dose corticosteroids groups (18, 20, 21, 23) .

Three RCT was assessed as low risk of bias (22, 24, 27) while the other one RCT was high risk of bias due to lack of random allocation of participants into high dose and low dose corticosteroids groups, which constituted potential selection bias (17) .

Eleven studies (n=2632) reported the mortality rate of COVID-19 patients after the administration of high dose and low dose corticosteroids ( Table 3 ). The mortality rate for high dose and low dose groups were 29% and 22%, respectively. Among these studies, there are three RCTs (22, 24, 27) , one quasi experimental study (17) and seven observational studies (16, (19) (20) (21) 23, 25, 26) . Our pooled analysis demonstrated no significant difference in the reduction of mortality rate between high dose and low dose corticosteroids (OR: 1.07 [95%CI 0.67, 1.72], p=0.77, I 2 =76%, certainty of evidence= very low).

In our subgroup analysis comparing between methylprednisolone (high dose group) versus dexamethasone (low dose group), four studies (n= 1091) were included in meta-analysis (17, 21, 22, 25) (Figure 3 ). Our result demonstrated no significant difference between high dose methylprednisolone and low dose dexamethasone (OR:0.84 [95 CI% 0.34, 2.07], p=0.70, I 2 =82%). In the trial sequential analysis, the minimum required information size for mortality was 13024 patients. At the current meta-analysis, with 2632 patients, only 20% of the required information size was available to detect or reject a relative risk reduction of 20% mortality rate, based on a 5% risk of Type 1 error (two-sided), a power of 80%, and an incidence in the control arm of 24.5% with a model variance-based heterogeneity correction.

Data of seven studies (n= 1544) (two RCTs (24, 27) , one quasi experimental study (17) and four observational studies (18, 21, 25, 26) were pooled for meta-analysis (Table 3 ). Our result revealed COVID-19 patients with high dose corticosteroids were not associated with lower ICU admission rate than the low dose corticosteroids group as compared to low dose corticosteroids (OR: 0.77[95%CI 0.43, 1.37], p=0.37, I 2 = 72%, certainty of evidence = very low).

Seven studies (n=1215) (three RCT (22, 24, 27) and four observational studies (16, 23, 25, 26) ) assessed the duration of hospital stay between the high dose and low dose corticosteroids groups ( p=0.58, I 2 =87%, certainty of evidence = very low).

Seven studies (n=1694) (three RCTs (22, 24, 27) , one quasi experimental study (17) and three observational studies (23, 25, 26) reported the number of people requiring respiratory support ( 

Three studies (n=419) (two RCTs (24, 27) and one observational study (26) (Table 3) .

Three studies (n=516) (one RCT (27) , one quasi experimental study (17) and one observational study (21) ), showed no significant difference in the incidence of hyperglycemia between the high dose and low dose corticosteroids groups (OR: 0.91[95%CI 0.58, 1.43], p=0.68, I 2 =0%, certainty of evidence = high) ( Table 3) .

Five studies (n=1485) (one RCT (27) , one quasi experimental study (17) and three observational studies (19, 21, 23) )were pooled for meta-analysis. Our result revealed no significant difference between high dose and low dose corticosteroids in infection rate (OR: 0.86[95%CI 0.64, 1.16], p=0.33, I 2 =29%, certainty of evidence = low) ( Table 3) .

To the best of our knowledge, this is the first meta-analysis comparing the efficacy and safety profile of high dose versus low dose corticosteroids in COVID-19 patients. Our meta-analysis demonstrated no significant differences in mortality rate, ICU admission rate, duration of hospital stays, number of people requiring respiratory support, duration of mechanical ventilation, incidence of hyperglycemia and infection rate between the high dose and low dose corticosteroids groups among COVID-19 patients. The certainty of evidence for all measured outcomes ranged very low to high due to observational studies, inconsistency, publication bias and dose-response gradient.

In our meta-analysis, our pooled data demonstrated that high dose corticosteroids were not superior to low dose corticosteroids in the reduction of mortality rate in COVID-19 patients.

The non-significant result can be due to multifactorial causes, namely different types, dosages and regimes (duration) of corticosteroids. In addition, our current meta-analysis has not achieved the minimum required information size for a conclusive finding. A recent study by the COVID STEROID 2 trial group involving COVID-19 patients with severe hypoxemia, 12 mg/d compared with 6 mg/d dexamethasone did not result in statistically significantly more days alive without life support at 28 days (34) . However, in its pre-planned Bayesian analysis of the trial, they found high probabilities of benefit with dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia on all outcomes, including the days alive without life support and mortality at day 28 and 90. They also found low probabilities of clinically important harm with 12 mg dexamethasone for all outcomes (35) .

In this study, the 2 doses used were still considered low dose, but there was a signal showing lower mortality in the higher dose group.

Corticosteroids inhibit pro-inflammatory protein synthesis (interleukin-6, interleukin-8, tumor necrosis factor, interferon γ) and induce the production of anti-inflammatory proteins (36, 37) . However, it comes with some adverse events, namely hyperglycemia, hypernatremia and neuromuscular weakness (36) (37) (38) . Whilst 7.5mg of prednisone or equivalent may slowly activate the effect of corticosteroids, the use of >100mg prednisone equivalent and pulse therapy (≥ 250mg prednisone equivalent) can rapidly saturate the cytoplasmic glucocorticoids receptors to activate fast onset of anti-inflammatory action (36) .

A prospective study showed 3 days of high dose pulsed corticosteroids therapy (at least 125mg methylprednisolone or its equivalent dexamethasone) significantly increased survival rate in COVID-19 patients (20) . Others reported the similar results with the use of 250mg/day methylprednisolone reduced mortality rate and shortened duration of hospitalization in COVID-19 induced ARDS patients (39, 40) . However, Tataki and colleagues reported that COVID-19 patients with an excessively high dose of pulsed corticosteroids therapy (1000mg/day methylprednisolone) were associated with a poorer prognosis (41) . Thus, the optimal dosage of pulsed corticosteroids therapy for COVID-19 patients warrants future adequately powered randomized trials for more clarity and evidence.

Our non-significant finding of mortality rate was similar with a meta-analysis by Cano et al.

comparing two groups (high dose corticosteroids vs no corticosteroids; low dose corticosteroids vs no corticosteroids) (42) . In our meta-analysis, we performed subgroup analysis based on different types of corticosteroids. We found that the mortality rate in the high dose corticosteroids group (methylprednisolone group) was not significantly lower than the low dose corticosteroids group (dexamethasone group). In other words, the mortality rate of COVID-19 patients does not improve with the use of methylprednisolone which it is believed that methylprednisolone has better lung penetration (43) . Ko and co-workers reported that methylprednisolone (1 mg/kg/d) has a significant mortality benefit than dexamethasone (6mg/day) in COVID-19 mechanical ventilated patients (44) . Ranjbar et al. compared methylprednisolone (2 mg/kg/day) and dexamethasone (6 mg/day) in hospitalized COVID-19 patients and found that those who received methylprednisolone had better clinical outcomes (22) . Due to the limited number of studies comparing methylprednisolone and dexamethasone, it is premature to determine the superiority of either methylprednisolone or dexamethasone in treating organizing pneumonia in COVID-19 patients. Therefore, future adequately powered studies can evaluate the efficacy of different types of corticosteroids in the treatment of COVID-19 organizing pneumonia.

Despite the desirable anti-inflammatory effect of corticosteroids, the safety profile of corticosteroids use in COVID-19 patients is inconclusive (17, 19, 21, 23, 27, 45, 46) . The

CoDEX trial demonstrated that 20mg of dexamethasone did not significantly increase the risk of new infections, bacteremia, or any increased insulin use for hyperglycemia, as compared to standard care group (46) . A meta-analysis revealed that the pulsed corticosteroids (>250 mg prednisone) were not associated with increased risk of side effects such as cardiac events, hyperglycemia, infections, hypertension, oedema, gastrointestinal and psychiatric adverse events (47) . Due to the limited data available, we only managed to pool the data for the incidence of hyperglycemia and infection rate between the high and low dose of corticosteroids groups. Our meta-analysis revealed no augmented risk of hyperglycemia and infection episodes in COVID-19 patients who received high dose of corticosteroids.

Monedero and colleagues also reported moderate to high dose corticosteroids (≥ 1mg/kg/d methylprednisolone or ≥ 0.12mg/kg/d dexamethasone) were not associated with higher risk of medical or infectious complications (45) .

Our pooled meta-analysis demonstrated no significant reduction of the ICU admission rate in the high dose corticosteroids group. Of note, many confounding factors namely underlying morbidities, obesity, baseline functional status, severity of organ failure introduced bias to the findings. However, Pareja et al. found that high dose corticosteroids (equivalent to ≥ 200mg methylprednisolone) were associated with lower mortality rate and ICU admission (48) .

Similarly, Pinzo'n and Munoz found that high dose corticosteroids (125-500mg/day methylprednisolone) has significantly reduced the ICU admission as compared to low dose group (18, 21) . This could be due to the patients who received corticosteroids were those who required oxygen support or more severe COVID-19 disease, which could denote more severe pulmonary involvement and inflammation. With higher dose corticosteroids, it could activate faster onset of anti-inflammatory action to achieve favorable outcomes.

In this review, there were no significant differences were observed in the duration of hospital stay, the number of people requiring respiratory support and the duration of mechanical ventilation. Different duration of corticosteroids regime was used across all included studies, which introduced variances to our findings (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . In contrast, a triple blinded RCT established that high dose corticosteroids significantly reduced the length of hospital stay and the number of people requiring respiratory support (2mg/kg methylprednisolone) as compared to low dose corticosteroids (6mg dexamethasone) (22) . High dose corticosteroids were generally used for less than 10 days in the reported studies, which were associated with a shorter duration of hospitalization and ventilation support (17, 21, 22, 44, 45, 48) . patients (ICU and non-ICU) were not performed due to limited data available for data pooling. In addition, the nature of observational studies with small sample size may introduce bias to our findings. Therefore, more adequately powered RCTs should be carried out to evaluate the efficacy of types, dosage, and duration of corticosteroids in the treatment of COVID-19.

In conclusion, our meta-analysis showed that low dose corticosteroids were as effective as high dose corticosteroids in the reduction of COVID-19 mortality rate. In view of substantial heterogeneity and low level of evidence, future adequately powered RCTs are warranted to increase certainty of evidence and minimize heterogeneity. 

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

COVID-19 in early 2021: current status and looking forward

A Review of the Evidence for Corticosteroids in COVID-19

Causes of death and comorbidities in hospitalized patients with COVID-19

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes

Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study

The COVID-19 Cytokine Storm; What We Know So Far

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

A comparison of COVID-19, SARS and MERS

Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review

Dexamethasone in Hospitalized Patients with Covid-19

Corticosteroids for COVID-19

World Health Organization

National Institutes of Health | COVID-19 Treatment Guidelines

Predictors of Coronavirus Disease 2019 Severity: A Retrospective Study of 64 Cases

Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease

High-dose versus low-dose corticosteroid treatment strategy in patients hospitalised with COVID-19: effect on ICU admission rate

High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study

High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response

Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

Efficacy of pulse steroid therapy in patients critically ill with COVID-19

Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial

High-dose methylprednisolone pulses for 3 days vs. Low-dose dexamethasone for 10 days in severe, non-critical covid-19: A retrospective propensity score matched analysis

ulse steroid treatment for hospitalized adults with COVID-19

Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 Pneumonia: an open-label, randomised clinical trial

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Estimating the mean and variance from the median, range, and the size of a sample

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

User manual for trial sequential analysis (TSA)

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

Genomic and nongenomic effects of glucocorticoids

Optimised glucocorticoid therapy: the sharpening of an old spear

A Review of the Evidence for Corticosteroids in COVID-19

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Before-After Study

The negative effect of initial high-dose methylprednisolone and tapering regimen for acute respiratory distress syndrome: a retrospective propensity matched cohort study

Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis

Penetration of corticosteroids into the lung: Evidence for a difference between methylprednisolone and prednisolone

A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19

Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

The safety of pulse corticosteroid therapy-Systematic review and meta-analysis

Efectividad de los glucocorticoides en pacientes hospitalizados por neumonía grave por SARS-CoV-2

FEM: Fixed-Effect Model; REM: Random-Effect Model; MD: Mean Difference; OR: Odd Ratio; VS: Versus =0

We thank Dr Enric Monreal for data sharing upon request.

This research did not receive specific grant from funding agencies in the public, commercial, or not-for profit sectors.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: